Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Management is prioritizing a diversified 'multiple shots on goal' model, leveraging two independently financed subsidiaries alongside a relaunched internal medical device portfolio.
Veris is transitioning from pilot to full-scale commercial engagement at Ohio State University, with two-thirds of planned departments now onboarded following successful EHR integration. The PortIO regulatory strategy is being aggressively re-evaluated; management believes recent first-in-human data publication may allow for a 510(k) pathway instead of the more capital-intensive De Novo route. Lucid Diagnostics remains the primary near-term value driver, with management focused on securing a positive Medicare Local Coverage Determination (LCD) as the critical catalyst.
Operational focus for the Veris implantable monitor has shifted to verification and validation testing following design enhancements that extended battery life beyond the 2-year target. The Octeris imaging platform is undergoing technical refinement at Duke University to improve processing speeds, aiming to support real-time clinical analysis during endoscopic procedures. Management targets an early 2027 FDA 510(k) submission for the Veris implantable physiologic monitor, with design freeze expected by the end of the current month.
A formal FDA pre-submission meeting request for PortIO is planned for the fourth quarter, which will determine if the shorter 510(k) regulatory path is viable. Operating expense increases are expected to be primarily driven by R&D requirements for the Veris implantable device through its submission and clearance phases. The Veris commercial strategy assumes reaching a target of 1,000 patient enrollments within the first year of the Ohio State University strategic partnership.
Octeris clinical validation work is contingent on IRB approval expected in October, though management notes the overall project remains several years from commercialization. The company completed a complex recapitalization, redeeming Series C preferred stock and retiring old debt through a $30 million Series D offering and a $15 million Senior Secured Note. A critical liquidity bridge exists in the form of $30 million in warrants that are only callable by the company upon the publication of a positive EsoGuard LCD.
PAVmed has transitioned from voting control to 'significant influence' over Lucid Diagnostics, maintaining a 25% voting interest despite owning 15% of common shares. First-in-human study results for PortIO published in the Journal of Vascular Access showed 100% device patency and no device-related adverse events, serving as the primary evidence for regulatory reclassification. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
